sub:assertion {
  d:DB00022 v:identifier "DB00022" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00022" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00022> ;
    dv:drugbank-id "BIOD00048" , "BTD00048" , "DB00022" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:08:18.20> ;
    dv:x-atc <http://bio2rdf.org/atc:L03AB10> ;
    dv:x-cas <http://bio2rdf.org/cas:99210-65-8> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2242966> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0085-1323-01> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164784024> ;
    dv:x-uniprot <http://bio2rdf.org/uniprot:P01563> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Peginterferon_alfa-2b> ;
    dct:description "Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule."@en ;
    dct:identifier "drugbank:DB00022" ;
    dct:title "Peginterferon alfa-2b"@en ;
    a dv:Drug ;
    rdfs:label "Peginterferon alfa-2b [drugbank:DB00022]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00022> , <http://www.drugs.com/cdi/peginterferon-alfa-2b.html> , <http://www.rxlist.com/cgi/generic2/peginterferon.htm> .
}